Horizon Pharma PLC (NASDAQ:HZNP) – Research analysts at Jefferies Group decreased their Q3 2017 earnings per share estimates for Horizon Pharma PLC in a note issued to investors on Tuesday. Jefferies Group analyst D. Steinberg now expects that the biopharmaceutical company will earn $0.19 per share for the quarter, down from their previous estimate of $0.25. Jefferies Group has a “Buy” rating and a $14.00 price objective on the stock. Jefferies Group also issued estimates for Horizon Pharma PLC’s FY2018 earnings at $0.95 EPS.
Horizon Pharma PLC (NASDAQ:HZNP) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.29. The company had revenue of $289.51 million for the quarter, compared to the consensus estimate of $237.01 million. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. The company’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.56 EPS.
WARNING: “Horizon Pharma PLC to Post Q3 2017 Earnings of $0.19 Per Share, Jefferies Group Forecasts (HZNP)” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/2796202/horizon-pharma-plc-to-post-q3-2017-earnings-of-0-19-per-share-jefferies-group-forecasts-hznp.html.
A number of other research analysts have also commented on HZNP. UBS AG set a $16.00 price objective on Horizon Pharma PLC and gave the company a “buy” rating in a research report on Wednesday, June 7th. BMO Capital Markets reiterated an “outperform” rating and issued a $18.00 price objective (up from $17.00) on shares of Horizon Pharma PLC in a research report on Thursday. Mizuho reiterated a “neutral” rating and issued a $9.00 price objective (down from $10.00) on shares of Horizon Pharma PLC in a research report on Wednesday. BidaskClub downgraded Horizon Pharma PLC from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $17.00 price target (up previously from $13.00) on shares of Horizon Pharma PLC in a research note on Wednesday. Five equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Horizon Pharma PLC has an average rating of “Buy” and a consensus target price of $19.86.
Shares of Horizon Pharma PLC (NASDAQ:HZNP) opened at 11.94 on Thursday. The stock’s 50 day moving average price is $12.44 and its 200-day moving average price is $13.70. The firm’s market capitalization is $1.94 billion. Horizon Pharma PLC has a 12 month low of $9.45 and a 12 month high of $23.44.
A number of hedge funds have recently modified their holdings of HZNP. Teachers Advisors LLC increased its stake in shares of Horizon Pharma PLC by 3.3% in the fourth quarter. Teachers Advisors LLC now owns 892,711 shares of the biopharmaceutical company’s stock valued at $14,444,000 after buying an additional 28,363 shares during the last quarter. Creative Planning increased its stake in Horizon Pharma PLC by 45.6% in the first quarter. Creative Planning now owns 122,502 shares of the biopharmaceutical company’s stock valued at $1,811,000 after buying an additional 38,354 shares in the last quarter. Graybill Bartz & Assoc Ltd. increased its stake in Horizon Pharma PLC by 1.6% in the first quarter. Graybill Bartz & Assoc Ltd. now owns 165,260 shares of the biopharmaceutical company’s stock valued at $2,443,000 after buying an additional 2,620 shares in the last quarter. First Manhattan Co. purchased a new stake in Horizon Pharma PLC during the first quarter valued at about $295,000. Finally, Profund Advisors LLC increased its stake in Horizon Pharma PLC by 0.8% in the first quarter. Profund Advisors LLC now owns 13,508 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 112 shares in the last quarter. 82.95% of the stock is currently owned by institutional investors and hedge funds.
Horizon Pharma PLC announced that its board has initiated a stock buyback plan on Monday, May 8th that permits the company to repurchase 1,000% of outstanding shares. This repurchase authorization permits the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.
Horizon Pharma PLC Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.